相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
Joseph Meserve et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis
Robert Battat et al.
INFLAMMATORY BOWEL DISEASES (2019)
Anti-MAdCAM Antibody Increases beta 7+T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's Disease
Mina Hassan-Zahraee et al.
JOURNAL OF CROHNS & COLITIS (2018)
Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
Tal Engel et al.
JOURNAL OF CROHNS & COLITIS (2018)
Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study
W. Yacoub et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
A. Barre et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
ACG Clinical Guideline: Management of Crohn's Disease in Adults (vol 113, pg 481, 2018)
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases
Erwin Dreesen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease
Elisa K. Boden et al.
DIGESTIVE DISEASES AND SCIENCES (2018)
Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study
Amy L. Lightner et al.
INFLAMMATORY BOWEL DISEASES (2018)
Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study
Stephane Paul et al.
JOURNAL OF CROHNS & COLITIS (2018)
Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease
Cindy C. Y. Law et al.
JOURNAL OF CROHNS & COLITIS (2018)
A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients
Hermann Schulze et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2018)
Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations
A. L. Lightner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
LONG-TERM EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 5-YEAR CUMULATIVE EXPOSURE OF GEMINI 1 COMPLETERS ROLLING INTO THE GEMINI OPEN-LABEL EXTENSION STUDY
Edward V. Loftus et al.
GASTROENTEROLOGY (2017)
Surgical Outcomes in Vedolizumab-Treated Patients with Ulcerative Colitis
Amy L. Lightner et al.
INFLAMMATORY BOWEL DISEASES (2017)
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2017)
The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo
Sebastian Zundler et al.
INFLAMMATORY BOWEL DISEASES (2017)
DOP020 Higher vedolizumab levels are associated with deep remission in patients with Crohn's disease and ulcerative colitis on maintenance therapy with vedolizumab
A. Yarur et al.
Journal of Crohns & Colitis (2017)
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease
Maria Rosario et al.
JOURNAL OF CROHNS & COLITIS (2017)
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C. Ng et al.
LANCET (2017)
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
Carl Eriksson et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2017)
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Friederike Fuchs et al.
FRONTIERS IN IMMUNOLOGY (2017)
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months
Nicolas Williet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease
W. A. Bye et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab
Jessica R. Allegretti et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice
Emily E. Vivio et al.
JOURNAL OF CROHNS & COLITIS (2016)
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
D. C. Baumgart et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
A. Stallmach et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S. Dulai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers
Maria Rosario et al.
CLINICAL DRUG INVESTIGATION (2016)
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
Aurelien Amiot et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial
M. Scott Harris et al.
JOURNAL OF CROHNS & COLITIS (2016)
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
M. Rosario et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Ulcerative Colitis Care Pathway
Themistocles Dassopoulos et al.
GASTROENTEROLOGY (2015)
Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus
Brian Bressler et al.
GASTROENTEROLOGY (2015)
Vedolizumab for Induction and Maintenance of Remission in Ulcerative Colitis: A Cochrane Systematic Review and Meta-analysis
Mahmoud H. Mosli et al.
INFLAMMATORY BOWEL DISEASES (2015)
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort
Edward Shelton et al.
INFLAMMATORY BOWEL DISEASES (2015)
Epidemiology and risk factors for IBD
Ashwin N. Ananthakrishnan
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results
Tim Wyant et al.
GUT (2015)
Optimizing anti-TNF treatments in inflammatory bowel disease
Shomron Ben-Horin et al.
AUTOIMMUNITY REVIEWS (2014)
Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Bruce E. Sands et al.
GASTROENTEROLOGY (2014)
O-003 Relationship Between Vedolizumab Pharmacokinetics and Endoscopic Outcomes of Patients With Ulcerative Colitis
Rosario Maria et al.
INFLAMMATORY BOWEL DISEASES (2014)
Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
Asit Parikh et al.
INFLAMMATORY BOWEL DISEASES (2013)
Declining Risk of Colorectal Cancer in Inflammatory Bowel Disease: An Updated Meta-analysis of Population-based Cohort Studies
Maurice W. M. D. Lutgens et al.
INFLAMMATORY BOWEL DISEASES (2013)
Antagonizing the α4β1 Integrin, but Not α4β7, Inhibits Leukocytic Infiltration of the Central Nervous System in Rhesus Monkey Experimental Autoimmune Encephalomyelitis
Krista G. Haanstra et al.
JOURNAL OF IMMUNOLOGY (2013)
Vedolizumab, a monoclonal antibody to the gut homing 01.4137 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype
Catherine Milch et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes
Timothy Wyant et al.
MABS (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements
Alain Bitton et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
Eric R. Fedyk et al.
INFLAMMATORY BOWEL DISEASES (2012)
Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study
Asit Parikh et al.
INFLAMMATORY BOWEL DISEASES (2012)
Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort
Stephan R. Vavricka et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
Adedigbo A. Fasanmade et al.
CLINICAL THERAPEUTICS (2011)
MEDICAL PROGRESS Ulcerative Colitis
Silvio Danese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rare Neurological Condition Linked to Newer Monoclonal Antibody Biologics
Bridget M. Kuehn
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-alpha(4)beta(7) Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Dulce Soler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
Yiping Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Brian G. Feagan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin
BG Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bioassay detects soluble MAdCAM-1 in body fluids
E Leung et al.
IMMUNOLOGY AND CELL BIOLOGY (2004)
Long-term evolution of disease behavior of Crohn's disease
J Cosnes et al.
INFLAMMATORY BOWEL DISEASES (2002)
An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC).
BG Feagan et al.
GASTROENTEROLOGY (2000)
分享论文
